echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Antibiotic treatment of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, a list of recommendations from European guidelines!

    Antibiotic treatment of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, a list of recommendations from European guidelines!

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yimaitong compiles and organizes, please do not reprint without authorization
    .

    In December 2021, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) issued guidelines for the treatment of multidrug-resistant Gram-negative bacilli infections
    .

    This article proposes guidance and recommendations for targeted antibiotic therapy of third-generation cephalosporin-resistant enterobacteria and carbapenem-resistant gram-negative bacteria, regarding carbapenem-resistant Pseudomonas aeruginosa (CRPA) and For the antibiotic treatment of carbapenem-resistant Acinetobacter baumannii (CRAB), the guidelines mainly have the following recommendations
    .

    Carbapenem-resistant Pseudomonas aeruginosa (CRPA) 1.
    CRPA antibiotic selection ➤ For patients with severe infection caused by refractory and drug-resistant CRPA (DTR-CRPA), it is recommended to use ceftaroza/tazobactam ( If effective in vitro) (conditional recommendation, very low quality of evidence)

    .

    At present, there is not enough evidence to confirm that imipenem-relebactam, cefadil and ceftazidime-avibactam are available
    .

    ➤For non-severe or low-risk CRPA infections, consider antibiotic management.
    Based on the individual patient and the source of infection, use old antibiotics with in vitro activity to treat

    .

    (Good practice statement) 2.
    Treatment of CRPA infections (combination and monotherapy) ➤Due to lack of evidence, it is not recommended to use new β-lactam/β-lactamase inhibitors (BLBLIs) (ceftazidime-avibactam and ceftrol) Za/tazobactam) or cefadil in the treatment of CRPA infection

    .

    ➤When using polymyxin, aminoglycoside or fosfomycin to treat severe infections caused by CRPA, two drugs with in vitro activity are recommended (conditional recommendation, very low-quality evidence)
    .

    There are no recommendations for or against specific drug combinations
    .

    ➤For patients with non-severe infections or low-risk CRPA infections, consider antibiotic management.
    Among drugs with in vitro activity, select single-agent treatment based on the individual patient and the source of infection

    .

    (Good practice statement) Carbapenem-resistant Acinetobacter baumannii (CRAB) 1.
    CRAB antibiotic selection ➤ For CRAB infection and sensitive to sulbactam and HAP/VAP patients, ampicillin/sulbactam is recommended

    .

    (Conditional recommendation, low quality of evidence) ➤For patients with CRAB infection and resistance to sulbactam, if they have in vitro activity, they can be treated with polymyxin or high-dose tigecycline
    .

    Due to lack of evidence, there is no recommendation for the antibiotic of choice
    .

      ➤Cefadil is not recommended to treat infections caused by CRAB
    .

    (Not recommended with conditions, low quality of evidence) 2.
    Treatment of CRAB infection (combination and monotherapy) ➤ For all patients with CRAB infection, polymyxin-meropenem combination therapy is not recommended (strong not recommended, high quality of evidence) ) Or polymyxin-rifampicin combination therapy (strong not recommended, moderate quality of evidence)

    .

    ➤For patients with severe or high-risk CRAB infection, it is recommended to choose a combination of two drugs with in vitro activity among the available antibiotics (polymyxin, aminoglycoside, tigecycline, and sulbactam combination)
    .

    (Conditional recommendation, very low quality of evidence) ➤For patients with CRAB infection and meropenem MIC <8 mg/L, consider carbapenem combination therapy and apply high-dose extended carbapenem infusion
    .

    (Good Practice Statement) Reference source: Paul M, Carrara E, Retamar P, et al.
    European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine).
    Clin Microbiol Infect.
    2021 Dec 16:S1198-743X(21)00679-0.
    doi: 10.
    1016/j.
    cmi.
    2021.
    11.
    025.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.